IgAN
World Congress of Nephrology (WCN) 2024
Buenos Aires, Argentina
April 13-16, 2024
Abstracts and Posters
ORIGIN 3: Pivotal Phase 3 Study Evaluating Effect of Atacicept vs Placebo on Proteinuria and Renal Function Preservation in IgAN
Barratt J, et al.
Atacicept in IgAN: Maintained Immunity From Diphtheria and Tetanus and Balanced Infections vs Placebo With a Focus on COVID-19
Barratt J, et al.
Atacicept Reduces Hematuria and Serum Gd-IgA1, Both Associated With Long-Term Renal Outcomes in IgAN: 36 Week Results From the Phase 2b ORIGIN Study
Barratt J, et al.